WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 26.5 HKD -5.36% Market Closed
Market Cap: 107.7B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+10%
Revenue
Forecast
+15%
Operating Income
Forecast
+19%
Net Income
Forecast
+22%

Wall Street
Price Targets

Price Targets Summary
WuXi Biologics (Cayman) Inc

Wall Street analysts forecast WuXi Biologics (Cayman) Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for WuXi Biologics (Cayman) Inc is 29.03 HKD with a low forecast of 10.1 HKD and a high forecast of 47.25 HKD.

Lowest Forecast
Wall Street Target
10.1 HKD
62% Downside
Average Forecast
Wall Street Target
29.03 HKD
10% Upside
Highest Forecast
Wall Street Target
47.25 HKD
78% Upside
Lowest
Price Target
10.1 HKD
62% Downside
Average
Price Target
29.03 HKD
10% Upside
Highest
Price Target
47.25 HKD
78% Upside
WuXi Biologics (Cayman) Inc Competitors:
Price Targets
VIMTALABS
Vimta Labs Ltd
22% Upside
PPGN
PolyPeptide Group AG
41% Upside
DIM
Sartorius Stedim Biotech SA
25% Upside
SHC
Sotera Health Co
35% Upside
VIMTALABS
Vimta Labs Ltd
22% Upside
PPGN
PolyPeptide Group AG
41% Upside
DIM
Sartorius Stedim Biotech SA
25% Upside
SHC
Sotera Health Co
35% Upside
CRL
Charles River Laboratories International Inc
7% Upside
300759
Pharmaron Beijing Co Ltd
23% Upside
AZTA
Azenta Inc
28% Upside
R
RVTY
Revvity Inc
37% Upside

Revenue
Forecast

Revenue Estimate
WuXi Biologics (Cayman) Inc

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's revenue is 44%. The projected CAGR for the next 3 years is 15%.

44%
Past Growth
15%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
WuXi Biologics (Cayman) Inc

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's operating income is 46%. The projected CAGR for the next 3 years is 19%.

46%
Past Growth
19%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
WuXi Biologics (Cayman) Inc

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's net income is 49%. The projected CAGR for the next 3 years is 22%.

49%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is WuXi Biologics (Cayman) Inc's stock price target?
Price Target
29.03 HKD

According to Wall Street analysts, the average 1-year price target for WuXi Biologics (Cayman) Inc is 29.03 HKD with a low forecast of 10.1 HKD and a high forecast of 47.25 HKD.

What is WuXi Biologics (Cayman) Inc's Revenue forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's revenue is 44%. The projected CAGR for the next 3 years is 15%.

What is WuXi Biologics (Cayman) Inc's Operating Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's operating income is 46%. The projected CAGR for the next 3 years is 19%.

What is WuXi Biologics (Cayman) Inc's Net Income forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for WuXi Biologics (Cayman) Inc's net income is 49%. The projected CAGR for the next 3 years is 22%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.